Remove Disease Remove Research Laboratories Remove Treatment
article thumbnail

NGS is evolving: collaboration and tech lead the way

Drug Target Review

The latest technologies are empowering researchers with faster, more efficient and more accessible genomic tools, leading to richer data generation and accelerating progress in areas like cancer genomics, rare disease research and infectious disease surveillance.​ hours to 24 hours.

RNA 91
article thumbnail

Merck’s WINREVAIR Succeeds in Phase 3 Trial for Pulmonary Arterial Hypertension

The Pharma Data

These findings represent a pivotal advancement in the treatment of this rare, progressive, and life-threatening disease. Participants were classified as WHO Group 1 PAH, functional class (FC) II or III, indicating moderate to severe disease at either intermediate or high risk of clinical deterioration.

Trials 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Phase 3 Trial of Ifinatamab Deruxtecan Begins in Advanced Prostate Cancer

The Pharma Data

While localized prostate cancer boasts a five-year survival rate above 90% , that figure drops precipitously to approximately 31% for metastatic disease. Current treatment strategies for mCRPC typically begin with ARPIs such as enzalutamide or abiraterone, followed by taxane-based chemotherapy , most commonly docetaxel.

Trials 40
article thumbnail

FDA Approves Merck’s ENFLONSIA™ to Prevent RSV in Infants

The Pharma Data

This new monoclonal antibody therapy is designed to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in neonates and infants born during or entering their first RSV season. Dr. Octavio Ramilo, Chair of the Department of Infectious Diseases at St. A New Era in Infant RSV Protection Dr. Dean Y.

article thumbnail

Merck’s ENFLONSIA Receives ACIP Recommendation for Protecting Infants from Severe RSV

The Pharma Data

Merck’s ENFLONSIA Receives ACIP Endorsement for RSV Prevention in Infants, Marking a Major Milestone in Pediatric Infectious Disease Prevention U.S. The disease burden is disproportionately high among infants under 1 year of age, and even more so among premature infants or those with underlying heart or lung conditions. As the U.S.

Vaccine 52
article thumbnail

FDA Grants Priority Review for WINREVAIR Label Update Based on ZENITH Trial

The Pharma Data

and Canada, has announced a significant regulatory milestone for its pulmonary arterial hypertension (PAH) treatment, WINREVAIR™ (sotatercept-csrk). Importantly, the treatment effect emerged early in the course of therapy and continued to increase over time. Despite existing therapies, many PAH patients remain at substantial risk.

Trials 52
article thumbnail

Edwin Cohn and the Harvard Blood Factory

Codon

The same team also invented several other products that proved useful for treating battlefield injuries, including gamma globulins to inoculate soldiers against diseases and fibrin film to minimize bleeding during brain surgeries. Still, Cohn’s work ought to be iconic amongst those interested in scientific progress and metascience.